EUVIMEDEUVIMED entdecken
Crossref

Dihydroartemisinin, a novel YTHDF2 inhibitor, alleviates rheumatoid arthritis by suppressing neutrophil extracellular traps via an autophagy-dependent pathway

Zhaoran Wang, Yi Jiao, Tong Shi, Chaoying Wen, Jiahe Xu, Tiantian Deng, Yan Wang, Tingting Deng, Cheng Huang, Yuan Xu, Cheng Xiao

Phytomedicine · 2026-07 · 156 · 158239

DOI: 10.1016/j.phymed.2026.158239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-07. Verfasst von Zhaoran Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: Artemisinins, Arthritis, Rheumatoid, Extracellular Traps, Autophagy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China-Japan Friendship Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Neutrophil extracellular traps (NETs) are pivotal in the pathogenesis of rheumatoid arthritis (RA). Although dihydroartemisinin (DHA) has shown efficacy in arthritis animal models, its mechanism of NETs regulation remains unknown. OBJECTIVES: Given the emerging role of m6A modification in immune cell activation, we investigated whether DHA alleviates RA by targeting an m6A-related mechanism in neutrophils. METHODS: We evaluated the therapeutic effect of DHA in collagen-induced arthritis (CIA) and K/BxN serum arthritis models. NETs were quantified by immunofluorescence and ELISA. Using transcriptomic data from RA patients, we identified key m6A regulators, which were validated in clinical samples. The target of DHA was verified through molecular docking, molecular dynamics simulations and a CETSA. The specific molecular mechanism through which DHA mediates neutrophil activation was elucidated through RIP-qPCR and mRNA stability assay. RESULTS: DHA significantly alleviated arthritis and inhibited NETs formation both in vivo and in vitro. We found that the protein YT521-B homology domain family protein 2 (YTHDF2), an m6A reader, is highly upregulated in RA neutrophils and critical for NETs formation. DHA directly binds to YTHDF2 and inhibits its function. Mechanistically, YTHDF2 recognizes m6A modifications on mTOR mRNA to promote its degradation, thereby driving NETs formation. Consequently, by targeting YTHDF2, DHA stabilized mTOR mRNA and inhibited NETs formation. CONCLUSION: Our research showed that the YTHDF2-mTOR-NETs axis is a novel pathogenic axis in RA. We further demonstrated that DHA, as a novel YTHDF2 inhibitor, acts through this axis, providing new mechanistic insights into RA pathogenesis and laying the foundation for targeting neutrophil m6A modification for the treatment of RA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtemisininsArthritis, RheumatoidExtracellular TrapsAutophagyRNA-Binding ProteinsAnimalsHumansNeutrophilsMaleMiceMolecular Docking SimulationArthritis, ExperimentalFemaleMice, Inbred DBA

Stichwörter der Autor:innen

DihydroartemisininNeutrophilRheumatoid arthritisYT521-B homology domain family protein 2 (YTHDF2)mTOR

Substanzen

ArtemisininsartenimolRNA-Binding Proteins

Autor:innen und Institutionen

  • China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100029, China; Institute of Clinical Medical Sciences, China-Japan Fr…
  • Department of Emergency, China-Japan Friendship Hospital, Beijing 100029, China.
  • Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China.
  • Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China; Beijing University of Chinese Medicine, China-Japan Friendship Hospital Clinical Medicine, Beijing 100029, China.
  • Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China.
  • Department of Orthopaedic Surgery, China-Japan Friendship Hospital, Beijing, China. Electronic address: hcheng90@outlook.com.

Förderung

  • National Natural Science Foundation of China
  • China-Japan Friendship Hospital

Zitieren

APA

Wang, Z., Jiao, Y., Shi, T., Wen, C., Xu, J., Deng, T., Wang, Y., Deng, T., Huang, C., Xu, Y., & Xiao, C. (2026). Dihydroartemisinin, a novel YTHDF2 inhibitor, alleviates rheumatoid arthritis by suppressing neutrophil extracellular traps via an autophagy-dependent pathway. Phytomedicine, 156, 158239. https://doi.org/10.1016/j.phymed.2026.158239

Vancouver

Wang Z, Jiao Y, Shi T, Wen C, Xu J, Deng T, et al. Dihydroartemisinin, a novel YTHDF2 inhibitor, alleviates rheumatoid arthritis by suppressing neutrophil extracellular traps via an autophagy-dependent pathway. Phytomedicine. 2026;156:158239. doi:10.1016/j.phymed.2026.158239

BibTeX
@article{Wang2026,
  author = {Wang, Zhaoran and Jiao, Yi and Shi, Tong and Wen, Chaoying and Xu, Jiahe and Deng, Tiantian and Wang, Yan and Deng, Tingting and Huang, Cheng and Xu, Yuan and Xiao, Cheng},
  title = {Dihydroartemisinin, a novel YTHDF2 inhibitor, alleviates rheumatoid arthritis by suppressing neutrophil extracellular traps via an autophagy-dependent pathway},
  journal = {Phytomedicine},
  year = {2026},
  volume = {156},
  pages = {158239},
  doi = {10.1016/j.phymed.2026.158239}
}
Kostenlos starten →